176 related articles for article (PubMed ID: 23711861)
1. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
2. Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
Yalcin AD; Bisgin A; Kargi A; Gorczynski RM
Med Sci Monit; 2012 Mar; 18(3):PI11-5. PubMed ID: 22367138
[TBL] [Abstract][Full Text] [Related]
3. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
[TBL] [Abstract][Full Text] [Related]
4. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.
Gill MA; Liu AH; Calatroni A; Krouse RZ; Shao B; Schiltz A; Gern JE; Togias A; Busse WW
J Allergy Clin Immunol; 2018 May; 141(5):1735-1743.e9. PubMed ID: 28870461
[TBL] [Abstract][Full Text] [Related]
5. A mobile instrumentation platform to distinguish airway disorders.
Schivo M; Seichter F; Aksenov AA; Pasamontes A; Peirano DJ; Mizaikoff B; Kenyon NJ; Davis CE
J Breath Res; 2013 Mar; 7(1):017113. PubMed ID: 23446184
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study.
Tajiri T; Suzuki M; Nishiyama H; Ozawa Y; Kurokawa R; Takeda N; Ito K; Fukumitsu K; Kanemitsu Y; Mori Y; Fukuda S; Uemura T; Ohkubo H; Takemura M; Maeno K; Ito Y; Oguri T; Izuhara K; Niimi A
Allergol Int; 2024 Jul; 73(3):406-415. PubMed ID: 38472036
[TBL] [Abstract][Full Text] [Related]
7. Improved small airway dysfunction in severe asthma with clinical remission by anti-interleukin-5/interleukin-5 receptor α.
Akamatsu T; Shirai T; Okawa K; Hirai K
Ann Allergy Asthma Immunol; 2024 May; 132(5):648-650. PubMed ID: 38360105
[No Abstract] [Full Text] [Related]
8. Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation.
Skiepko R; Ziętkowski Z; Lukaszyk M; Budny W; Skiepko U; Milewski R; Bodzenta-Łukaszyk A
Postepy Dermatol Alergol; 2014 Oct; 31(5):305-9. PubMed ID: 25395927
[TBL] [Abstract][Full Text] [Related]
9. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
11. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
Macglashan DW; Saini SS
J Allergy Clin Immunol; 2013 Oct; 132(4):906-11.e1-4. PubMed ID: 23791510
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Teramoto T; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2017 Jan; 66(1):106-115. PubMed ID: 27507228
[TBL] [Abstract][Full Text] [Related]
15. Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion.
Honma W; Gautier A; Paule I; Yamaguchi M; Lowe PJ
Drug Metab Pharmacokinet; 2016 Jun; 31(3):173-84. PubMed ID: 27238573
[TBL] [Abstract][Full Text] [Related]
16. Impact of omalizumab on medical cost of childhood asthma in Japan.
Yoshikawa H; Iwata M; Matsuzaki H; Ono R; Murakami Y; Taba N; Honjo S; Motomura C; Odajima H
Pediatr Int; 2016 May; 58(5):425-8. PubMed ID: 27173421
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
Yalcin AD; Celik B; Yalcin AN
Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):253-6. PubMed ID: 27121601
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
Clavenna MJ; Turner JH; Samuelson M; Tanner SB; Duncavage J; Chandra RK
Allergy Asthma Proc; 2016; 37(1):23-6. PubMed ID: 26831843
[TBL] [Abstract][Full Text] [Related]
19. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
[TBL] [Abstract][Full Text] [Related]
20. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
